Tumor suppressor role of microRNA-1296 in triple-negative breast cancer
Authors:
Open Access
- 20 January 2016
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (15) , 19519-19530
Abstract
Tumor suppressor role of microRNA-1296 in triple-negative breast cancerKeywords
This publication has 38 references indexed in Scilit:
- Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trialThe Lancet Oncology, 2015
- Colorectal cancer screening using protected microRNAs2011
- MicroRNAs in Development and DiseasePhysiological Reviews, 2011
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- Regulation of Minichromosome Maintenance Gene Family by MicroRNA-1296 and Genistein in Prostate CancerCancer Research, 2010
- Platinum-based chemotherapy in triple-negative breast cancerAnnals of Oncology, 2008
- Cyclin D1 in Breast Cancer PathogenesisJournal of Clinical Oncology, 2005
- Minireview: Cyclin D1: Normal and Abnormal FunctionsEndocrinology, 2004
- Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck.1995
- Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic miceNature, 1994